US Stock Market Move | Q2 performance exceeds expectations and raises full-year performance guidance Johnson & Johnson (JNJ.US) rose more than 6% at one point.

On Wednesday, Johnson & Johnson (JNJ.US) rose over 6% at one point, marking its largest intraday gain since July 2023, and is now trading at $162.20. On the news front, the company's second-quarter performance exceeded Wall Street expectations and raised its full-year guidance, showing confidence in its growth amidst the dual threats of tariffs and drug price reductions in the pharmaceutical industry. The financial report shows that Johnson & Johnson's quarterly sales reached $23.7 billion, surpassing analysts' average expectations of $22.8 billion. The second-quarter earnings per share under non-GAAP were $2.77, higher than the market's expectation by $0.09. Johnson & Johnson has raised the midpoint of its 2025 revenue outlook by $2 billion to $93.4 billion and adjusted its full-year earnings per share outlook by $0.25 to a range of $10.80-10.90.